Dose-reduced
Clinical Trials Overview
1 trials found
About Dose-reduced
The use of dose-reduced chemotherapy or targeted therapies in colorectal cancer (CRC) is often tailored to individual patient tolerance and toxicity profiles. These agents may be used across various lines of therapy, including adjuvant settings after surgery, as part of first-line regimens for metastatic disease, or in later lines when initial treatments are no longer effective.
Category
Otras Medicaciones
Brand Name
** This applies to virtually all cancer medications including chemotherapy agents (carboplatin, paclitaxel, doxorubicin), targeted therapies (trastuzumab, imatinib), and immunotherapy drugs (pembrolizumab, nivolumab) - any brand name cancer drug may be do
Mechanism
The mechanism of action varies widely depending on the specific drug and its pharmacological category; for example, chemotherapy drugs like carboplatin inhibit DNA synthesis and repair in rapidly dividing cells, while targeted therapies such as trastuzumab block HER2 receptors to prevent cancer cell proliferation.
Efficacy Data by Mutation
Response rates and survival outcomes by patient molecular profile
Biomarker-unselected All patients
2A
47%
ORR
7.9m
PFS
20.4m
OS
n=62
Sample
Biomarker-unselected All patients
2A
22%
ORR
5.5m
PFS
19m
OS
n=58
Sample
1
Total Trials
1
Recruiting
0
Active
0
Completed
587
Total Enrollment
1
Countries
Active sites for Dose-reduced
Recruiting sites
1 countries
NCT06275958
Phase 3
Recruiting
587 patients
Medications:
Dose-reduced
Monotherapy
The goal of this phase III, open-label, non-inferiority randomized controlled clinical trial is compare upfront dose-reduced chemotherapy with the standard dose chemotherapy in older patients ( ≥70 years) with metastasized colorectal cancer, with r...
Netherlands